Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Lucid Diagnostics (NASDAQ:LUCD) and maintained a $3 price target.
May 15, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Lucid Diagnostics (NASDAQ:LUCD) and maintained a $3 price target.
The reiteration of an Overweight rating and the maintenance of a $3 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100